

- Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European and African-American men and women. *Pharmacogenetics* 13:595-606.
- Foisy MM, Yakiwchuk EM, Chiu I and Singh AE (2008) Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. *HIV Med* 9:389-396.
- Foradori A, Mezzano S, Videla C, Pefaur J and Elberg A (1998) Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants. *Transplant Proc* 30:1685-1687.
- Fuhr U (1998) Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. *Drug Saf* 18:251-272.
- Fujita K (2004) Food-drug interactions via human cytochrome P450 3A (CYP3A). *Drug Metabol Drug Interact* 20:195-217.
- Fukasawa T, Yasui-Furukori N, Suzuki A, Inoue Y, Tateishi T and Otani K (2005) Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. *Eur J Clin Pharmacol* 61:791-795.
- Funck-Brentano C, Becquemont L, Kroemer HK, Buhl K, Knebel NG, Eichelbaum M and Jaillon P (1994) Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. *Clin Pharmacol Ther* 55:256-269.
- Funck-Brentano C, Kroemer HK, Pavlou H, Woosley RL and Roden DM (1989a) Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. *Br J Clin Pharmacol* 27:435-444.
- Funck-Brentano C, Turgeon J, Woosley RL and Roden DM (1989b) Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. *J Pharmacol Exp Ther* 249:134-142.
- Furberg CD and Pitt B (2001) Withdrawal of cerivastatin from the world market. *Curr Control Trials Cardiovasc Med* 2:205-207.
- Furuta T, Sugimoto M, Shirai N and Ishizaki T (2007) CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. *Pharmacogenomics* 8:1199-1210.
- Galetin A, Brown C, Halifax D, Ito K and Houston JB (2004) Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5,

- and CYP2C19 on CYP3A4 probe substrates. *Drug Metab Dispos* **32**:1411-1420.
- Galetin A, Burt H, Gibbons L and Houston JB (2006) Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. *Drug Metab Dispos* **34**:166-175.
- Galetin A, Ito K, Hallifax D and Houston JB (2005) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. *J Pharmacol Exp Ther* **314**:180-190.
- Garcia-Martin E, Martinez C, Tabares B, Frias J and Agundez JA (2004) Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. *Clin Pharmacol Ther* **76**:119-127.
- Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P and Desmeules J (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. *N Engl J Med* **351**:2827-2831.
- Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P and Maurel P (1989) The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450III<sub>A</sub> induction. *Br J Clin Pharmacol* **28**:373-387.
- Gentile DM, Tomlinson ES, Maggs JL, Park BK and Back DJ (1996) Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. *J Pharmacol Exp Ther* **277**:105-112.
- Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, Brobst SW, Segal Y and Aberg JA (2005) Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. *J Acquir Immune Defic Syndr* **39**:307-312.
- Gibbs MA, Thummel KE, Shen DD and Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of  $K_i$  values and impact of CYP3A5 expression. *Drug Metab Dispos* **27**:180-187.
- Giusti DL and Hayton WL (1973) Dosage regimen adjustments in renal impairment. *Drug Intell Clin Pharm* **7**:382-387.
- Glaeser H, Drescher S, Eichelbaum M and Fromm MF (2005) Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. *Br J Clin Pharmacol* **59**:199-206.
- Gomez DY, Wachter VJ, Tomlanovich SJ, Hebert MF and Benet LZ (1995) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. *Clin Pharmacol Ther* **58**:15-19.
- Goodwin B, Hodgson E and Liddle C (1999) The orphan human pregnane X receptor

- mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. *Mol Pharmacol* **56**:1329-1339.
- Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Jr. and Hall SD (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. *Clin Pharmacol Ther* **64**:133-143.
- Granfors MT, Backman JT, Laitila J and Neuvonen PJ (2005) Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. *Clin Pharmacol Ther* **78**:400-411.
- Granfors MT, Backman JT, Neuvonen M, Ahonen J and Neuvonen PJ (2004a) Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. *Clin Pharmacol Ther* **75**:331-341.
- Granfors MT, Backman JT, Neuvonen M and Neuvonen PJ (2004b) Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. *Clin Pharmacol Ther* **76**:598-606.
- Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol AL, Mertzanis P, Duan SX, Wright CE and Shader RI (1998a) Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. *Clin Pharmacol Ther* **64**:278-285.
- Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL and Shader RI (2000) Differential impairment of triazolam and zolpidem clearance by ritonavir. *J Acquir Immune Defic Syndr* **24**:129-136.
- Greenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S and Shader RI (1998b) Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. *Clin Pharmacol Ther* **64**:237-247.
- Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J and Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. *J Clin Invest* **104**:147-153.
- Grimm SW, Richtand NM, Winter HR, Stams KR and Reece SB (2006) Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. *Br J Clin Pharmacol* **61**:58-69.
- Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. *Annu Rev Pharmacol Toxicol* **39**:1-17.
- Hamaoka N, Oda Y, Hase I and Asada A (2001) Cytochrome P4502B6 and 2C9 do not

- metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies. *Br J Anaesth* **86**:540-544.
- Hamelin BA, Bouayad A, Methot J, Jobin J, Desgagnes P, Poirier P, Allaire J, Dumesnil J and Turgeon J (2000) Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. *Clin Pharmacol Ther* **67**:466-477.
- Hamman MA, Bruce MA, Haehner-Daniels BD and Hall SD (2001) The effect of rifampin administration on the disposition of fexofenadine. *Clin Pharmacol Ther* **69**:114-121.
- Hasselstrom J and Linnet K (2006) In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. *Drug Metabol Drug Interact* **21**:187-211.
- Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP and Wallemacq P (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. *Pharmacogenetics* **14**:147-154.
- Heimark LD, Gibaldi M, Trager WF, O'Reilly RA and Goulart DA (1987) The mechanism of the warfarin-rifampin drug interaction in humans. *Clin Pharmacol Ther* **42**:388-394.
- Heinig R, Adelmann HG and Ahr G (1999) The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine. *Eur J Clin Pharmacol* **55**:57-60.
- Hemeryck A, Lefebvre RA, De Vriendt C and Belpaire FM (2000) Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. *Clin Pharmacol Ther* **67**:283-291.
- Henshall J, Galetin A, Harrison A and Houston JB (2008) Comparative analysis of CYP3A heteroactivation by steroid hormones and flavonoids in different in vitro systems and potential in vivo implications. *Drug Metab Dispos* **36**:1332-1340.
- Hewitt NJ, Lecluyse EL and Ferguson SS (2007) Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. *Xenobiotica* **37**:1196-1224.
- Hirota N, Ito K, Iwatsubo T, Green CE, Tyson CA, Shimada N, Suzuki H and Sugiyama Y (2001) In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. *Biopharm Drug Dispos* **22**:53-71.
- Ho PC, Ghose K, Saville D and Wanwimolruk S (2000) Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy

- volunteers. *Eur J Clin Pharmacol* **56**:693-698.
- Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE and Heidemann H (1996) The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. *Drug Metab Dispos* **24**:1121-1123.
- Houston JB and Galetin A (2003) Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. *Drug Metab Rev* **35**:393-415.
- Houston JB and Galetin A (2005) Modelling atypical CYP3A4 kinetics: principles and pragmatism. *Arch Biochem Biophys* **433**:351-360.
- Huang SM, Temple R, Throckmorton DC and Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. *Clin Pharmacol Ther* **81**:298-304.
- Hynninen VV, Olkkola KT, Neuvonen PJ and Laine K (2009) Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. *Eur J Clin Pharmacol* **65**:89-95.
- Ieiri I, Kimura M, Irie S, Urae A, Otsubo K and Ishizaki T (2005) Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. *Pharmacogenet Genomics* **15**:851-859.
- Ingelman-Sundberg M (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. *Trends Pharmacol Sci* **25**:193-200.
- Ingelman-Sundberg M, Sim SC, Gomez A and Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoeconomic and clinical aspects. *Pharmacol Ther* **116**:496-526.
- Ishigam M, Uchiyama M, Kondo T, Iwabuchi H, Inoue S, Takasaki W, Ikeda T, Komai T, Ito K and Sugiyama Y (2001) Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. *Pharm Res* **18**:622-631.
- Ito K, Brown HS and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. *Br J Clin Pharmacol* **57**:473-486.
- Ito K, Hallifax D, Obach RS and Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. *Drug Metab Dispos* **33**:837-844.
- Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y and Sugiyama Y (1998a) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. *Annu Rev Pharmacol Toxicol* **38**:461-499.
- Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H and Sugiyama Y (1998b) Prediction of

- pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. *Pharmacol Rev* **50**:387-412.
- Ito K, Ogihara K, Kanamitsu S and Itoh T (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. *Drug Metab Dispos* **31**:945-954.
- Jalava KM, Olkkola KT and Neuvonen PJ (1997) Itraconazole greatly increases plasma concentrations and effects of felodipine. *Clin Pharmacol Ther* **61**:410-415.
- Jolivet L and Ekins S (2007) Methods for predicting human drug metabolism. *Adv Clin Chem* **43**:131-176.
- Jonsson G, Astrom A and Andersson P (1995) Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. *Drug Metab Dispos* **23**:137-142.
- Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N and Sugiyama Y (2000a) Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. *Pharm Res* **17**:419-426.
- Kanamitsu S, Ito K and Sugiyama Y (2000b) Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. *Pharm Res* **17**:336-343.
- Kanamitsu SI, Ito K, Okuda H, Ogura K, Watabe T, Muro K and Sugiyama Y (2000c) Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. *Drug Metab Dispos* **28**:467-474.
- Kantola T, Backman JT, Niemi M, Kivisto KT and Neuvonen PJ (2000) Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. *Eur J Clin Pharmacol* **56**:225-229.
- Kantola T, Kivisto KT and Neuvonen PJ (1998a) Effect of itraconazole on the pharmacokinetics of atorvastatin. *Clin Pharmacol Ther* **64**:58-65.
- Kantola T, Kivisto KT and Neuvonen PJ (1998b) Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. *Clin Pharmacol Ther* **64**:177-182.
- Kantola T, Kivisto KT and Neuvonen PJ (1998c) Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. *Clin Pharmacol Ther* **63**:397-402.
- Kato M, Chiba K, Horikawa M and Sugiyama Y (2005) The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. *Drug Metab Pharmacokinet* **20**:236-243.

- Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T and Sugiyama Y (2008) The Quantitative Prediction of CYP-mediated Drug Interaction by Physiologically Based Pharmacokinetic Modeling. *Pharm Res*.
- Kaye CM and Nicholls B (2000) Clinical pharmacokinetics of ropinirole. *Clin Pharmacokinet* **39**:243-254.
- Kent UM, Juschyshyn MI and Hollenberg PF (2001) Mechanism-based inactivators as probes of cytochrome P450 structure and function. *Curr Drug Metab* **2**:215-243.
- Kenworthy KE, Bloomer JC, Clarke SE and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. *Br J Clin Pharmacol* **48**:716-727.
- Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ and Levy RH (1994) Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. *Biochem Pharmacol* **47**:1969-1979.
- Kim MK, Cho JY, Lim HS, Hong KS, Chung JY, Bae KS, Oh DS, Shin SG, Lee SH, Lee DH, Min B and Jang IJ (2003) Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. *Eur J Clin Pharmacol* **59**:111-116.
- Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C and Roots I (2002a) Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. *Clin Pharmacol Ther* **71**:286-296.
- Kirchheiner J, Meineke I, Muller G, Bauer S, Rohde W, Meisel C, Roots I and Brockmoller J (2004) Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. *Clin Pharmacokinet* **43**:267-278.
- Kirchheiner J, Meineke I, Muller G, Roots I and Brockmoller J (2002b) Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. *Pharmacogenetics* **12**:571-580.
- Kirchheiner J, Muller G, Meineke I, Wernecke KD, Roots I and Brockmoller J (2003) Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. *J Clin Psychopharmacol* **23**:459-466.
- Kirchheiner J and Seeringer A (2007) Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. *Biochim Biophys Acta* **1770**:489-494.
- Kivisto KT, Kantola T and Neuvonen PJ (1998) Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. *Br J Clin Pharmacol* **46**:49-53.
- Kivisto KT, Lamberg TS and Neuvonen PJ (1999) Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. *Pharmacol Toxicol* **84**:94-97.

- Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. *Biochemistry* **37**:4137-4147.
- Kostrubsky VE, Ramachandran V, Venkataramanan R, Dorko K, Esplen JE, Zhang S, Sinclair JF, Wrighton SA and Strom SC (1999) The use of human hepatocyte cultures to study the induction of cytochrome P-450. *Drug Metab Dispos* **27**:887-894.
- Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J and Gerber N (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. *Drug Metab Dispos* **26**:552-561.
- Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M and Schmoouder RL (2005) Blood concentrations of everolimus are markedly increased by ketoconazole. *J Clin Pharmacol* **45**:514-518.
- Kowey PR, Kirsten EB, Fu CH and Mason WD (1989) Interaction between propranolol and propafenone in healthy volunteers. *J Clin Pharmacol* **29**:512-517.
- Kubota H (2001) Number of drugs in Japan from the administrative standpoint of new drug approval and medical *Clinical Evaluation* **28**:505-511.
- Kumar GN, Rodrigues AD, Buko AM and Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. *J Pharmacol Exp Ther* **277**:423-431.
- Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ and Krahenbuhl S (1995) Interaction between grapefruit juice and midazolam in humans. *Clin Pharmacol Ther* **58**:20-28.
- Lam YW, Alfaro CL, Ereshefsky L and Miller M (2003) Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. *J Clin Pharmacol* **43**:1274-1282.
- Lamba JK, Lin YS, Schuetz EG and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. *Adv Drug Deliv Rev* **54**:1271-1294.
- Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF and Christians U (1998) Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. *J Pharmacol Exp Ther* **285**:1104-1112.
- Lebrun-Vignes B, Archer VC, Diquet B, Levron JC, Chosidow O, Puech AJ and Warot D (2001) Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. *Br J Clin Pharmacol*



51:443-450.

- Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT and Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. *J Clin Invest* **102**:1016-1023.
- Lepesheva GI and Waterman MR (2007) Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. *Biochim Biophys Acta* **1770**:467-477.
- Lessard E, Yessine MA, Hamelin BA, Gauvin C, Labbe L, O'Hara G, LeBlanc J and Turgeon J (2001) Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. *J Clin Psychopharmacol* **21**:175-184.
- Li AP, Reith MK, Rasmussen A, Gorski JC, Hall SD, Xu L, Kaminski DL and Cheng LK (1997) Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. *Chem Biol Interact* **107**:17-30.
- Lilja JJ, Kivisto KT and Neuvonen PJ (2000) Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. *Clin Pharmacol Ther* **68**:384-390.
- Lin JH (2006) CYP induction-mediated drug interactions: in vitro assessment and clinical implications. *Pharm Res* **23**:1089-1116.
- Lin JH and Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. *Clin Pharmacokinet* **35**:361-390.
- Liu P, Foster G, Gandelman K, LaBadie RR, Allison MJ, Gutierrez MJ and Sharma A (2007) Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. *Antimicrob Agents Chemother* **51**:3617-3626.
- Matsumoto S, Ding LR, Ishii M, Fischer NE and Inaba T (2002) The interaction of human and bovine serum proteins with CYP3A in human liver microsomes: inhibition of testosterone 6beta-hydroxylation by albumin, alpha-globulins, alpha(1)-acid glycoprotein and gamma-globulins. *Toxicol Lett* **136**:33-41.
- Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J and Sundaresen P (2000) Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. *Clin Pharmacol Ther* **68**:391-400.
- McConn DJ, 2nd, Lin YS, Allen K, Kunze KL and Thummel KE (2004) Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. *Drug Metab Dispos* **32**:1083-1091.
- McGinnity DF, Parker AJ, Soars M and Riley RJ (2000) Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. *Drug Metab Dispos* **28**:1327-1334.

- McKillop D, McCormick AD, Millar A, Miles GS, Phillips PJ and Hutchison M (2005) Cytochrome P450-dependent metabolism of gefitinib. *Xenobiotica* **35**:39-50.
- Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E and Sabatine MS (2008) Cytochrome P-450 Polymorphisms and Response to Clopidogrel. *N Engl J Med*.
- Michalets EL (1998) Update: clinically significant cytochrome P-450 drug interactions. *Pharmacotherapy* **18**:84-112.
- Mikus G, Schowel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, Burhenne J, Weiss J, Thomsen T and Haefeli WE (2006) Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. *Clin Pharmacol Ther* **80**:126-135.
- Muck W, Wingender W, Seiberling M, Woelke E, Ramsch KD and Kuhlmann J (1992) Influence of the H<sub>2</sub>-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers. *Eur J Clin Pharmacol* **42**:325-328.
- Muirhead GJ, Faulkner S, Harness JA and Taubel J (2002) The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. *Br J Clin Pharmacol* **53** Suppl 1:37S-43S.
- Muirhead GJ, Wulff MB, Fielding A, Kleinermans D and Buss N (2000) Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. *Br J Clin Pharmacol* **50**:99-107.
- Nakashima D, Takama H, Ogasawara Y, Kawakami T, Nishitoba T, Hoshi S, Uchida E and Tanaka H (2007) Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. *J Clin Pharmacol* **47**:1311-1319.
- Naline E, Sanceaume M, Pays M and Advenier C (1988) Application of theophylline metabolite assays to the exploration of liver microsome oxidative function in man. *Fundam Clin Pharmacol* **2**:341-351.
- Nelson MV, Berchou RC, Kareti D and LeWitt PA (1990) Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. *Clin Pharmacol Ther* **47**:694-697.
- Neuvonen PJ and Jalava KM (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. *Clin Pharmacol Ther* **60**:54-61.
- Neuvonen PJ, Kantola T and Kivisto KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. *Clin Pharmacol Ther* **63**:332-341.

- Newton DJ, Wang RW and Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. *Drug Metab Dispos* **23**:154-158.
- Nielsen KK, Brosen K, Hansen MG and Gram LF (1994) Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. *Clin Pharmacol Ther* **55**:518-527.
- Niemi M, Backman JT, Fromm MF, Neuvonen PJ and Kivisto KT (2003) Pharmacokinetic interactions with rifampicin: clinical relevance. *Clin Pharmacokinet* **42**:819-850.
- Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ and Kivisto KT (2001) Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. *Clin Pharmacol Ther* **69**:194-200.
- Niwa T, Murayama N, Emoto C and Yamazaki H (2008a) Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. *Curr Drug Metab* **9**:20-33.
- Niwa T, Murayama N and Yamazaki H (2008b) Heterotropic cooperativity in oxidation mediated by cytochrome p450. *Curr Drug Metab* **9**:453-462.
- Niwa T, Shiraga T, Ishii I, Kagayama A and Takagi A (2005a) Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. *Biol Pharm Bull* **28**:1711-1716.
- Niwa T, Shiraga T and Takagi A (2005b) [Drug-drug interaction of antifungal drugs]. *Yakugaku Zasshi* **125**:795-805.
- O'Reilly RA, Goulart DA, Kunze KL, Neal J, Gibaldi M, Eddy AC and Trager WF (1992) Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. *Clin Pharmacol Ther* **51**:656-667.
- O'Reilly RA, Trager WF, Rettie AE and Goulart DA (1987) Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. *Clin Pharmacol Ther* **42**:290-294.
- Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. *J Pharmacol Exp Ther* **316**:336-348.
- Obach RS, Walsky RL, Venkatakrishnan K, Houston JB and Tremaine LM (2005) In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. *Clin Pharmacol Ther* **78**:582-592.
- Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR and Bailey DG (2001) Red wine-cisapride interaction: comparison with grapefruit juice. *Clin Pharmacol Ther*

70:17-23.

- Ohno Y, Hisaka A and Suzuki H (2007) General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of Standard Drugs. *Clin Pharmacokinet* 46:681-696.
- Ohno Y, Hisaka A, Ueno M and Suzuki H (2008) General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. *Clin Pharmacokinet* 47:669-680.
- Olkkola KT, Ahonen J and Neuvonen PJ (1996) The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. *Anesth Analg* 82:511-516.
- Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ and Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. *Clin Pharmacol Ther* 53:298-305.
- Olkkola KT, Backman JT and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. *Clin Pharmacol Ther* 55:481-485.
- Omar G, Whiting PH, Hawksworth GM, Humphrey MJ and Burke MD (1997) Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. *Ther Drug Monit* 19:436-445.
- Osanai T, Ohkubo T, Yasui N, Kondo T and Kaneko S (2004) Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. *Br J Clin Pharmacol* 58:476-481.
- Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, Leonard JM and Granneman GR (1998) Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. *Br J Clin Pharmacol* 46:111-116.
- Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM and Kalow W (1997) Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. *Clin Pharmacol Ther* 62:334-347.
- Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE and Zeldin DC (2006a) The human intestinal cytochrome P450 "pie". *Drug Metab Dispos* 34:880-886.
- Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD and Thummel KE (1997) Characterization of interintestinal and intrainestinal variations in human CYP3A-dependent metabolism. *J Pharmacol Exp Ther* 283:1552-1562.
- Paine MF, Widmer WW, Hart HL, Pusek SN, Beavers KL, Criss AB, Brown SS, Thomas BF and Watkins PB (2006b) A furanocoumarin-free grapefruit juice establishes

- furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. *Am J Clin Nutr* **83**:1097-1105.
- Palkama VJ, Ahonen J, Neuvonen PJ and Olkkola KT (1999) Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. *Clin Pharmacol Ther* **66**:33-39.
- Pang KS and Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. *J Pharmacokinet Biopharm* **5**:625-653.
- Parsons WD and Neims AH (1978) Effect of smoking on caffeine clearance. *Clin Pharmacol Ther* **24**:40-45.
- Patki KC, Von Moltke LL and Greenblatt DJ (2003) In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. *Drug Metab Dispos* **31**:938-944.
- Patsalos PN and Perucca E (2003) Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. *Lancet Neurol* **2**:473-481.
- Pearson JT, Wahlstrom JL, Dickmann LJ, Kumar S, Halpert JR, Wienkers LC, Foti RS and Rock DA (2007) Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. *Chem Res Toxicol* **20**:1778-1786.
- Pichard L, Gillet G, Bonfils C, Domergue J, Thenot JP and Maurel P (1995) Oxidative metabolism of zolpidem by human liver cytochrome P450S. *Drug Metab Dispos* **23**:1253-1262.
- Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK and Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *Bmj* **329**:15-19.
- Polasek TM and Miners JO (2006) Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. *Eur J Clin Pharmacol* **62**:203-208.
- Pope LE, Khalil MH, Berg JE, Stiles M, Yakatan GJ and Sellers EM (2004) Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. *J Clin Pharmacol* **44**:1132-1142.
- Popper H, Czygan P, Greim H, Schaffner F and Garro AJ (1973) Mutagenicity of primary and secondary carcinogens altered by normal and induced hepatic microsomes. *Proc*

*Soc Exp Biol Med* **142**:727-729.

- Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ and Tweedie D (2000) Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. *Br J Clin Pharmacol* **49 Suppl 1**:35S-42S.
- Projean D, Morin PE, Tu TM and Ducharme J (2003) Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes. *Xenobiotica* **33**:841-854.
- Reilly PE, Mason SR and Read MA (1999) Human, rat and crocodile liver microsomal monooxygenase activities measured using diazepam and nifedipine: effects of CYP3A inhibitors and relationship to immunochemically detected CYP3A apoprotein. *Comp Biochem Physiol C Pharmacol Toxicol Endocrinol* **122**:197-204.
- Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. *Drug Metab Rev* **29**:413-580.
- Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS and de Morais SM (2006) Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. *Drug Metab Dispos* **34**:1742-1748.
- Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. *Biochem Pharmacol* **57**:465-480.
- Rodrigues AD, Roberts EM, Mulford DJ, Yao Y and Ouellet D (1997) Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. *Drug Metab Dispos* **25**:623-630.
- Rodrigues AD and Rushmore TH (2002) Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. *Curr Drug Metab* **3**:289-309.
- Rogers JF, Nafziger AN and Bertino JS, Jr. (2002) Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. *Am J Med* **113**:746-750.
- Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. *Nat Rev Drug Discov* **6**:140-148.
- Rowland A, Elliot DJ, Knights KM, Mackenzie PI and Miners JO (2008) The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated

- fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. *Drug Metab Dispos* **36**:870-877.
- Rudberg I, Hermann M, Refsum H and Molden E (2008) Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. *Eur J Clin Pharmacol* **64**:1181-1188.
- Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ and Olkkola KT (2006) Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. *Clin Pharmacol Ther* **79**:362-370.
- Saito M, Hirata-Koizumi M, Matsumoto M, Urano T and Hasegawa R (2005a) Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. *Drug Saf* **28**:677-694.
- Saito M, Hirata-Koizumi M, Urano T, Miyake S and Hasegawa R (2005b) A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. *J Clin Pharm Ther* **30**:21-37.
- Saitoh H and Aungst BJ (1995) Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. *Pharm Res* **12**:1304-1310.
- Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF and Watkins PB (1997) Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. *Drug Metab Dispos* **25**:1228-1233.
- Seidegard J (2000) Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration. *Clin Pharmacol Ther* **68**:13-17.
- Shimizu T, Miyashita I, Matsubara Y, Ikeda M and Yamaguchi M (2006) [Pharmacokinetic profile of silodosin in clinical practice]. *Yakugaku Zasshi* **126 Spec no.**:257-263.
- Shitara Y, Hirano M, Adachi Y, Itoh T, Sato H and Sugiyama Y (2004) In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. *Drug Metab Dispos* **32**:1468-1475.
- Shitara Y and Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. *Pharmacol Ther* **112**:71-105.
- Silverman RB (1995) Mechanism-based enzyme inactivators. *Methods Enzymol* **249**:240-283.

- Simard C, Michaud V, Gibbs B, Masse R, Lessard E and Turgeon J (2004) Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. *Xenobiotica* **34**:1013-1023.
- Sindrup SH, Brosen K and Gram LF (1992) Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. *Clin Pharmacol Ther* **51**:288-295.
- Sinz M, Wallace G and Sahi J (2008) Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. *AAPS J* **10**:391-400.
- Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E and Caputi AP (1993) Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. *Ther Drug Monit* **15**:243-246.
- Spizhovi V, Kramer AA, Gasilin VS, Liakishev AA and Samoilenko LE (1983) [Use of myocardial scintigraphy with <sup>201</sup>Tl for differential diagnosis of ischemic heart disease and hypertrophic cardiomyopathy in women]. *Kardiologiya* **23**:51-55.
- Sproule BA, Naranjo CA, Brenner KE and Hassan PC (1997) Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. *Clin Pharmacokinet* **33**:454-471.
- Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z and Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. *J Natl Cancer Inst* **95**:1758-1764.
- Suzuki H and Sugiyama Y (2000) Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. *Eur J Pharm Sci* **12**:3-12.
- Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D and Wild MJ (2005) Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. *Clin Pharmacokinet* **44**:1067-1081.
- Swart PJ, Krauwinkel WJ, Smulders RA and Smith NN (2006) Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. *Basic Clin Pharmacol Toxicol* **99**:33-36.
- Takagi K, Hasegawa T, Yamaki K, Suzuki R, Watanabe T and Satake T (1988) Interaction between theophylline and enoxacin. *Int J Clin Pharmacol Ther Toxicol* **26**:288-292.
- Takahashi H, Kashima T, Kimura S, Murata N, Takaba T, Iwade K, Abe T, Tainaka H, Yasumori T and Echizen H (1999a) Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance. *Drug Metab Dispos* **27**:1179-1186.
- Takahashi H, Sato T, Shimoyama Y, Shioda N, Shimizu T, Kubo S, Tamura N, Tainaka H,



- Yasumori T and Echizen H (1999b) Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. *Clin Pharmacol Ther* **66**:569-581.
- Takanaga H, Ohnishi A, Murakami H, Matsuo H, Higuchi S, Urae A, Irie S, Furuie H, Matsukuma K, Kimura M, Kawano K, Orii Y, Tanaka T and Sawada Y (2000) Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. *Clin Pharmacol Ther* **67**:201-214.
- Tateishi T, Ohashi K, Sudo T, Sakamoto K, Toyosaki N, Hosoda S, Toyooka T, Kumagai Y, Sugimoto K, Fujimura A and et al. (1989) Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. *J Clin Pharmacol* **29**:994-997.
- Thomas PP, Manivannan J, John GT and Jacob CK (2004) Sirolimus and ketoconazole co-prescription in renal transplant recipients. *Transplantation* **77**:474-475.
- Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. *Clin Pharmacol Ther* **59**:491-502.
- Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen PJ and Backman JT (2008) The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. *Clin Pharmacol Ther* **84**:403-411.
- Trancon C, Leemann T, Vogt N and Dayer P (1995) In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. *Clin Pharmacol Ther* **58**:412-417.
- Tsunoda SM, Velez RL, von Moltke LL and Greenblatt DJ (1999) Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. *Clin Pharmacol Ther* **66**:461-471.
- Tucker GT, Houston JB and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential toward a consensus. *Pharm Res* **18**:1071-1080.
- Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ and Mjorndal T (2004) Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. *Eur J Clin Pharmacol* **59**:879-882.
- Uno T, Shimizu M, Yasui-Furukori N, Sugawara K and Tateishi T (2006) Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. *Br J Clin Pharmacol* **61**:309-314.
- Uttamsingh V, Lu C, Miwa G and Gan LS (2005) Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic

- metabolism of the proteasome inhibitor bortezomib. *Drug Metab Dispos* **33**:1723-1728.
- Varhe A, Olkkola KT and Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. *Clin Pharmacol Ther* **56**:601-607.
- Varis T, Kaukonen KM, Kivisto KT and Neuvonen PJ (1998) Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. *Clin Pharmacol Ther* **64**:363-368.
- Varis T, Kivisto KT, Backman JT and Neuvonen PJ (2000a) The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. *Clin Pharmacol Ther* **68**:487-494.
- Varis T, Kivisto KT and Neuvonen PJ (2000b) The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. *Eur J Clin Pharmacol* **56**:57-60.
- Venkatakrishnan K, Obach RS and Rostami-Hodjegan A (2007) Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. *Xenobiotica* **37**:1225-1256.
- Venkatakrishnan K, Schmider J, Harmatz JS, Ehrenberg BL, von Moltke LL, Graf JA, Mertzanis P, Corbett KE, Rodriguez MC, Shader RI and Greenblatt DJ (2001) Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. *J Clin Pharmacol* **41**:1043-1054.
- Venkatakrishnan K, von Moltke LL and Greenblatt DJ (1998) Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. *J Pharm Sci* **87**:845-853.
- Veronese ME, Miners JO, Randles D, Gregov D and Birkett DJ (1990) Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. *Clin Pharmacol Ther* **47**:403-411.
- Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequignot E, Waldman SA and Greenberg HE (2003) Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. *J Clin Pharmacol* **43**:831-839.
- Von Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, Harmatz JS and Shader RI (1999) Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. *Br J Clin Pharmacol* **48**:89-97.
- von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM,

- Pritchard GA, Wright CE and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. *J Pharmacol Exp Ther* **276**:370-379.
- Wacher VJ, Silverman JA, Zhang Y and Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. *J Pharm Sci* **87**:1322-1330.
- Wan J, Xia H, He N, Lu YQ and Zhou HH (1996) The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. *Br J Clin Pharmacol* **42**:471-474.
- Wang RW, Kari PH, Lu AY, Thomas PE, Guengerich FP and Vyas KP (1991) Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. *Arch Biochem Biophys* **290**:355-361.
- Wang RW, Newton DJ, Liu N, Atkins WM and Lu AY (2000) Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. *Drug Metab Dispos* **28**:360-366.
- Wang YH, Jones DR and Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. *Drug Metab Dispos* **32**:259-266.
- Wang YH, Jones DR and Hall SD (2005) Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. *Drug Metab Dispos* **33**:664-671.
- Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA and Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. *J Pharmacol Exp Ther* **306**:287-300.
- Warot D, Bergougnan L, Lamiable D, Berlin I, Bensimon G, Danjou P and Puech AJ (1987) Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. *Eur J Clin Pharmacol* **32**:389-393.
- Warrington JS, Shader RI, von Moltke LL and Greenblatt DJ (2000) In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. *Drug Metab Dispos* **28**:392-397.
- Werner U, Werner D, Rau T, Fromm MF, Hinz B and Brune K (2003) Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. *Clin Pharmacol Ther* **74**:130-137.
- Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, Kauffmann HM, Schrenk D, Terhaag B,

- Kroemer HK and Siegmund W (2000) Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. *Clin Pharmacol Ther* **68**:345-355.
- Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. *Nat Rev Drug Discov* **4**:825-833.
- Wijnands WJ, Vree TB and van Herwaarden CL (1986) The influence of quinolone derivatives on theophylline clearance. *Br J Clin Pharmacol* **22**:677-683.
- Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR and Ball SE (2004) Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUC<sub>i</sub>/AUC) ratios. *Drug Metab Dispos* **32**:1201-1208.
- Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. *Drug Metab Dispos* **30**:883-891.
- Winship LC, McKenney JM, Wright JT, Jr., Wood JH and Goodman RP (1985) The effect of ranitidine and cimetidine on single-dose diltiazem pharmacokinetics. *Pharmacotherapy* **5**:16-19.
- Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z and Woolsey J (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic Acids Res* **34**:D668-672.
- Wong M, Balleine RL, Collins M, Liddle C, Clarke CL and Gurney H (2004) CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. *Clin Pharmacol Ther* **75**:529-538.
- Wong YW, Yeh C and Thyrum PT (2001) The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. *J Clin Psychopharmacol* **21**:89-93.
- Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. *Crit Rev Toxicol* **22**:1-21.
- Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY and Wachter VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. *Clin Pharmacol Ther* **58**:492-497.
- Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y and Iga T (2001) Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. *Drug Metab Dispos* **29**:443-452.
- Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP and Shimada T (1997)